Innovative cancer medicines in China: questions for a specialist

Why the drug gap exists

Approvals and commercial availability differ between countries and change over time. Compare the current regulator information for the exact medicine and indication, with help from a licensed oncologist.

Questions about innovative cancer medicines

Domestic PD-1 / PD-L1 checkpoint inhibitors

Ask the oncologist which checkpoint inhibitor, if any, is relevant and request the current approved label and supporting evidence for the proposed indication.

Request an itemised written estimate from the hospital for your specific diagnosis and plan. Include medicines, tests, admission, follow-up and travel costs; generic country-level price comparisons are not a personal quotation.

Third-generation EGFR inhibitors

For lung cancer, the oncologist decides whether molecular testing is appropriate and how the findings affect treatment options. A mutation result alone does not establish eligibility for a medicine.

• Ask the oncologist to review the molecular findings and identify any appropriate EGFR-directed options, with the approved indication, evidence, risks and alternatives.
• Ask a licensed physician to confirm which options are appropriate for the diagnosis, prior treatment and current condition. Availability, eligibility, benefits and risks require case-specific hospital assessment.

ADC antibody-drug conjugates

For an antibody-drug conjugate, ask the oncologist about the exact product, current approved indication, required biomarkers, evidence, risks and alternatives. Approval in one country does not establish approval elsewhere.

Legality and safety — what patients ask most

Are these drugs legal?

Check the exact product and indication with the treating hospital and the relevant regulator. Prescribing, supply, export and import rules depend on the medicine and destination; do not assume a prescription authorises cross-border transport.

Is domestic drug quality reliable?

Ask the hospital for the regulator-approved product information and the evidence relevant to the proposed use. A general claim about national standards does not establish suitability or quality for a specific medicine.

How to find out if these drugs apply to your case

Prepare pathology, imaging, treatment history and any existing molecular reports for a licensed oncology team. The clinician decides whether more testing is needed and which options are appropriate.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. All treatment decisions should be made under the guidance of licensed medical professionals. WELLIN / WELLIN Pro International Health is a professional services and does not provide diagnosis or treatment.